Obesity Drugs

3 articles

Pfizer's giant hand shaking Metsera's smaller hand, symbolizing a $4.9 billion acquisition deal amidst a backdrop of glowing drug molecules and market growth charts.

Pfizer acquires Metsera in $4.9B deal amid biotech boom

Pfizer will pay $4.9 billion to acquire Metsera, a company whose shares debuted at just $18, after its lead obesity candidate showed 11.3% weight loss in early trials, according to Biospace . This mul

Maria Flores·June 29, 2026

A symbolic bridge representing Medicare's temporary copay program for obesity drugs, connecting patients to vital medications.

Cosmos & Physics

Medicare's temporary $50 copay for obesity drugs like Zepbound

Starting July 1, 2026, eligible Medicare Part D beneficiaries will access branded obesity drugs like Zepbound for a $50 monthly copay, an unprecedented expansion of coverage set to expire just 18 mont

Dr. Evelyn Reed·June 8, 2026

A scientist in a futuristic lab examining a holographic display of a triple hormone receptor drug, representing Pfizer's new obesity treatment.

Cosmos & Physics

Pfizer advances monthly obesity drug targeting triple hormone receptors

Pfizer is advancing a monthly weight-loss injection, danuglipron, having announced positive early-stage data.

Dr. Evelyn Reed·June 7, 2026